Century Therapeutics, Inc. (IPSC) Tops Q2 EPS by 7c

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.38), $0.07 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $800 thousand versus the consensus estimate of $430 thousand.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• S&P Global (SPGI) Declares $0.97 Quarterly Dividend; 1% Yield
• MacroGenics to receive $24.5M milestone from Sanofi on FDA approval